DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • India
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
BIOCON logo

Biocon Limited Stock Price

NSEI:BIOCON Community·₹639.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 28 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

BIOCON Share Price Performance

₹0
-362.15 (-100.00%)
​
₹446.89
Fair Value
₹0
-362.15 (-100.00%)
​
Price ₹0
Fri, 18 Sep 26
Fair Value₹446.89
Share Pricen/a

BIOCON Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value ₹446.89 12.7% undervalued intrinsic discount

Biosimilars Demand Will Unlock Global Market Opportunities

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value ₹326 19.6% overvalued intrinsic discount

Rising Regulatory Scrutiny And Supply Risks Will Hamper Biosimilars

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value ₹534 27.0% undervalued intrinsic discount

Growing Global Aging Demand Will Expand Affordable Biosimilars

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
BIOCON logo
Biocon
12.7% undervalued intrinsic discount
Updated

Biosimilars Demand Will Unlock Global Market Opportunities

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 18 Sep
Read Narrative
BIOCON logo
Biocon
19.6% overvalued intrinsic discount

Rising Regulatory Scrutiny And Supply Risks Will Hamper Biosimilars

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 4 Sep
Read Narrative
BIOCON logo
Biocon
27.0% undervalued intrinsic discount

Growing Global Aging Demand Will Expand Affordable Biosimilars

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 21 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
BIOCON logo

BIOCON: Biosimilar Launches And Brazil Partnership Will Support Future Upside

Fair Value: ₹446.89 12.7% undervalued intrinsic discount
16 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
BIOCON logo

BIOCON: Slower Margin Recovery Will Restrict Future P/E Upside

Fair Value: ₹326 19.6% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
BIOCON logo

BIOCON: Margin Execution And Cost Discipline Will Underpin Higher Fair Value

Fair Value: ₹534 27.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Reasonable growth potential with proven track record.

2 Risks
2 Rewards
View Full Analysis

Biocon Limited Key Details

₹173.2b

Revenue

₹67.2b

Cost of Revenue

₹106.0b

Gross Profit

₹101.0b

Other Expenses

₹5.0b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
3.06
61.19%
2.86%
42.1%
View Full Analysis

About BIOCON

Founded
1978
Employees
16447
CEO
Shreehas Tambe
WebsiteView website
www.biocon.com

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Recent BIOCON News & Updates

User avatar
Narrative Update • Sep 18

BIOCON: Biosimilar Launches And Brazil Partnership Will Support Future Upside

Analysts have lifted their price target on Biocon to ₹446.89 from ₹429.67. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E.
User avatar
Narrative Update • Sep 04

BIOCON: Slower Margin Recovery Will Restrict Future P/E Upside

Analysts have raised their fair value estimate for Biocon from ₹298.76 to ₹326.00, citing updated assumptions on revenue growth, margins, and future P/E that they believe better reflect the company’s long-term earnings potential. Analyst Commentary on Biocon While the higher fair value estimate signals more confidence in Biocon’s earnings power, not all commentary skews positive.
User avatar
Narrative Update • Aug 21

BIOCON: Margin Execution And Cost Discipline Will Underpin Higher Fair Value

Analysts have lifted their fair value estimate for Biocon to ₹534 from ₹506, citing slightly higher required returns, more moderate revenue growth assumptions, stronger profit margin expectations, and a lower future P/E multiple in their refreshed price target work. Analyst Commentary Bullish analysts looking at Biocon are framing the refreshed fair value as part of a broader move toward more disciplined expectations on returns, growth, and profitability.

Recent updates

No updates

Biocon Limited Competitors

SUNPHARMA logo

Sun Pharmaceutical Industries

Symbol: NSEI:SUNPHARMA
Market cap: ₹4.5t
DIVISLAB logo

Divi's Laboratories

Symbol: NSEI:DIVISLAB
Market cap: ₹2.5t
500420 logo

Torrent Pharmaceuticals

Symbol: BSE:500420
Market cap: ₹1.9t
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide